We investigated whether serum neutrophil gelatinase-associated lipocalin (NGAL) was an early predictive biomarker of contrast-induced nephropathy (CIN) in patients with chronic kidney disease (n = 100) undergoing coronary catheterization. Serum creatinine (SCr) levels were measured at baseline, 24 hours, and 48 hours post procedure. Serum NGAL was measured preprocedure, 4 hours, and 24 hours post procedure. The frequency of CIN was 11%. In patients with CIN, SCr achieved significance only at 48 hours (P = .006), whereas serum NGAL increased ≥25% from baseline at 24 hours in 7 of 11 patients with CIN (P = .04) but did not change in the other 4. However, serum NGAL also rose ≥25% in 12 of 89 non-CIN patients. This subgroup could have had “incipient CIN.” Serum NGAL delta value at baseline, 24 hours was superior to SCr for early diagnosis of CIN. In conclusion, serum NGAL is an early predictive biomarker for CIN.
NashKHafeezAHouS. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–936.
2.
McCulloughPAWolynRRocherLLLevinRNO’NeillWW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368–375.
3.
RudnickMRGoldfarbSWexlerL. For the iohexol cooperative study: nephrotoxicity of high-osmolality versus low- osmolality contrast media: a randomized trial. Kidney Int. 1995;47(1):254–261.
4.
GoldenbergIMatetzkyS. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461–1471.
5.
BriguoriCManganelliFScarpatoP. Acetylcysteine and contrast agent associated nephrotoxicity. J Am Coll Cardiol. 2002;40(2):298–303.
6.
TepelMAspelinPLameireN. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113(14):1799–1806.
7.
LetellierGDesjarlaisF.Analytical interference of drug in clinical chemistry: II - interference of three cephalosporins with the determination of serum creatinine concentration by the Jaffe reaction. Clin Biochem. 1985;18(6):352–356.
8.
WeberJAVan ZantenAP. Interferences in current methods for measurements of creatinine. Clin Chem. 1991;37(5):695–700.
9.
LingWZhaohuiNBenH. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008;108(3):176–181.
10.
Bachorzewska-GajewskaHMalyszkoJSitniewskaE. Could neutrophil gelatinase-associated lipocalin and cystatin C predict the development of contrast induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?Kidney Blood Press Res. 2007;30(6):408–415.
11.
RickliHBenouKAmmannP. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol. 2004;6(2):98–102.
12.
IshibashiYYamauchiMMushaHMikamiTKawasakiKMiyakeF. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization. Angiology. 2010;61(8):724–730.
13.
MoriKLeeHTRapoportD. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610–621.
14.
MishraJMaQKellyC. Kidney NGAL is a novel early marker of acute renal injury following transplantation. Pediatr Nephrol. 2006;21(6):856–863.
15.
LeveyASGreeneTKusekJWBeckGJ.A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol. 2000;11:A0828.
16.
BernsAS. Nephrotoxicity of contrast media. Kidney Int. 1989;36(4):730–740.
17.
MehranRAymongEDNikolskyE. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–1399.
18.
FuNLiXYangS. Risk Score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention. Angiology. 2013;64(3):188–194.
19.
Raposeiras-RoubínSAguiar-SoutoPBarreiro-PardalCGRACE risk score predicts contrast-induced nephropathy in patients with acute coronary syndrome and normal renal function. Angiology. 2013;64(1):31–39.
20.
ElbasanZSahinDYGürM. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology. 2014;65(1):37–42.
21.
SianosGMorelMAKappeteinAP. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. Eurointervention. 2005;1(2):219–227.
22.
KayJChowWHChanTM. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. A randomized controlled trial. JAMA. 2003;289(5):553–558.
23.
Diaz-SandovalLJKosowskyBDLosordoDW. Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trial). Am J Cardiol. 2002;89(3):356–358.
24.
ZainuddinS.A Comparison of Different Treatment Measures to Prevent Contrast-Induced Nephropathy in Patients With Underlying Stable Renal Impairment Undergoing Coronary Angiography. [MMED thesis]. Malaysia: Faculty of Medicine, Universiti Kebangsaan Malaysia; 2004. 9HUKM.WJ342.S681c.
25.
O'SullivanSHealyDAMoloneyMCGracePAWalshSR. The Role of N acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology. 2013;64(8):576–582.
26.
GoldenbergIShechterMMatetzkyS. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004;25(3):212–218.
27.
SeyonRAJensenLAFergusonIAWilliamsRG. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention. Heart Lung. 2007:36(3):195–204.
28.
MarenziGAssanelliEMaranaI. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354(26):2773–2782.
29.
AlonsoALauJJaberBLWeintraubASarnakMJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis. 2004;43(1):1–9.
30.
BirckRKrzossokSMarkowetzFSchnullePvan der WoudeFJBraunC. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362(9384):598–603.
31.
LiuRNairDIxJMooreDHBentS.N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med. 2005;20(2):193–200.
32.
NallamothuBKShojaniaKGSaintS. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med. 2004;117(12):938–947.
33.
MarenziGLauriGAssanelliE. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(9):1780–1785.
34.
GleesonTGBulugahapitiyaS. Contrast-induced nephropathy. AJR Am J Roentgenol. 2004;183(6):1673–1689.
35.
DetrenisSMeschiMMusiniSSavazziG. Lights and shadows on the pathogenesis of contrast induced nephropathy: state of the art. Nephrol Dial Transplant. 2005;20(8):1542–1550.
36.
ParfreyPSGriffithsSMBarrettBJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med. 1989;320(3):143–149.
37.
RihalCSTextorSCGrillDE. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259–2264.
38.
WeisbergLSKurnikPBKurnikBR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45(1):259–265.
39.
DangasGIakovouINikolskyE. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13–19.
BarrettBJCarlisleEJ. Meta-analysis of the relative nephrotoxicity of high – and low osmolitity iodinated contrast media. Radiology.1993;188(1):171–178.
42.
AspelinPAubryPFranssonSG. Nephrotoxic effects in high-risk patients undergoing angiography. N Eng J Med. 2003;348(6):491–499.
43.
CroninRE. Renal failure following radiologic procedures. Am J Med Sci. 1989;298(5): 342–356.
44.
MurphySWBarrettBJParfreyPS. Contrast nephropathy. J Am Soc Nephrol. 2000;11(1):177–182.
45.
DevarajanP.Emerging biomarkers of acute kidney injury. Contrib Nephrol. 2007;156:203–212.
46.
BolignanoDLacquanitiACoppolinoG. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):337–344.
47.
MitsnefesMMKathmanTSMishraJ. Serum neutrophil gelatinase associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol. 2007;22(1):101–108.
